Global Vinflunine Market, By Drug Class (Antineoplastics, Vinca Alkaloids), Indication (Oncology/Cancer, Others), Dosage Forms (Solution, Injections, Others), Route of Administration (Intravenous, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029
Market Analysis and Size
Cancer is the greatest cause of mortality worldwide, according to the World Health Organization (WHO), accounting for approximately 10 million deaths in 2020, or nearly one in every six deaths. Around 400,000 children are diagnosed with cancer every year. Vinflunine is a form of vinca alkaloids that is commonly used to treat cancer. It belongs to the third generation of vinca alkaloids having anti-tumor properties. It works by stimulating cell cycle arrest in the G2/M phase and promoting cell death through apoptosis. The European Medicines Agency approved it in 2009 as a second-line therapy for urothelial carcinoma when platinum treatment failed.
Data Bridge Market Research analyses that the vinflunine market was valued at USD 7.535 billion in 2021 and is expected to reach USD 16.39 billion by 2029, registering a CAGR of 10.20% during the forecast period of 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
2022 to 2029
2020 (Customizable to 2014 - 2019)
Revenue in USD Billion, Volumes in Units, Pricing in USD
Drug Class (Antineoplastics, Vinca Alkaloids), Indication (Oncology/Cancer, Others), Dosage Forms (Solution, Injections, Others), Route of Administration (Intravenous, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
Market Players Covered
AstraZeneca (U.K.), Johnson & Johnson Private Limited (U.S.), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd.(Israel), Fresenius Kabi AG (Germany), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), Sanofi (France), Merck & Co., Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Bristol-Myers Squibb Company (U.S.), Abbott (U.S.), Sagent Pharmaceuticals, Inc. (U.S.), Hikma Pharmaceuticals PLC (U.K.), Dr. Reddy’s Laboratories Ltd. (India), Eli Lilly and Company (U.S.), Aurobindo Pharma (India), Amneal Pharmaceuticals LLC. (U.S.)
After a platinum-based treatment has failed, vinflunine is a vinca alkaloid used to treat advanced or metastatic transitional cell carcinoma of the urothelial tract. Vinflunine's antitumor effects are depending on the drug's concentration and exposure time. Vinflunine inhibits microtubule assembly and reduces the rate and extent of microtubule growth events at micromolar doses, resulting in an anti-mitotic effect. In mice, vinflunine has anti-cancer effect against a wide range of human xenografts, both in terms of survival and tumor growth inhibition. In vitro, vinflunine is a less powerful activator of drug resistance than other vinca alkaloids.
Vinflunine Market Dynamics
- Increasing prevalence of cancer
The rising prevalence of cancer such as such as urothelial cancer, cell carcinoma and others is estimated to enhance the vinflunine market's growth rate. Urothelial carcinoma of the bladder is one of the most frequent cancers globally, with an annual incidence of 429,700 new cases and a fatality rate of 165,000. Approximately 80% of those affected are between the ages of 50 and 79. Surgical techniques are preferable for non-muscle-invasive bladder cancer and muscle-invasive locally restricted malignancies.
- Increasing investment for healthcare infrastructure
Another significant factor influencing the growth rate of vinflunine market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.
Furthermore, rising geriatric population and rise in demand for advanced cancer drugs will expand the vinflunine market. Additionally, growing level of disposable income and increasing number of government initiatives to spread awareness are estimated to enhance the market’s growth rate.
- Increase in the number of research and development activities
The vinflunine market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the vinflunine market growth. For instance, the IMvigor211-Trial is a multicentre, phase III, open-label, randomized trial that compares atezolizumab to chemotherapy in patients with locally advanced or metastatic urothelial carcinoma of the bladder who have failed platinum-containing first-line therapy. The medicine being studied is the PD1 inhibitor atezolizumab, however VFL is one of three active comparators because the investigator will be able to choose one of three chemotherapy regimens (VFL against paclitaxel or docetaxel) for each patient prior to randomization.
Moreover, increase in the number of emerging markets and new product launches will further provide beneficial opportunities for the vinflunine market growth during the forecast period.
On the other hand, the high cost associated with drug development and distribution will obstruct the market's growth rate. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the vinflunine market. Additionally, side effects of vinflunine such as nausea, vomiting, stomatitis, headache, dizziness, insomnia, chest congestion, bone pain, muscle weakness, and others and strict FDA guidelines for the drug approval of new drug will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.
This vinflunine market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the vinflunine market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
Vinflunine market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Global Vinflunine Market Scope
The vinflunine market is segmented on the basis of drug class, indication, dosage forms, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
- Vinca Alkaloids
Route of Administration
- Specialty Clinics
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Vinflunine Market Regional Analysis/Insights
The vinflunine market is analysed and market size insights and trends are provided by country, drug class, indication, dosage forms, route of administration, end-users and distribution channel as referenced above.
The countries covered in the vinflunine market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America dominates the vinflunine market because of the strong presence of key manufacture of the product and rising healthcare expenditure in this region. Additionally, high research and development expenditure and the presence of skilled professionals will further propel the market’s growth rate in this region.
Asia-Pacific is expected to grow during the forecast period due to increased government awareness programs and rising healthcare expenditure in this region. Also, the growing number of generic drugs will further cushion the market’s growth rate in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Vinflunine Market Share Analysis
The vinflunine market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to vinflunine market.
Some of the major players operating in the vinflunine market are:
- AstraZeneca (U.K.)
- Johnson & Johnson Private Limited (U.S.)
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd.(Israel)
- Fresenius Kabi AG (Germany)
- Pfizer Inc. (U.S.)
- GlaxoSmithKline plc (U.K.)
- Novartis AG (Switzerland)
- Sanofi (France)
- Merck & Co., Inc. (U.S.)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Bristol-Myers Squibb Company (U.S.)
- Abbott (U.S.)
- Sagent Pharmaceuticals, Inc. (U.S.)
- Hikma Pharmaceuticals PLC (U.K.)
- Dr. Reddy’s Laboratories Ltd. (India)
- Eli Lilly and Company (U.S.)
- Aurobindo Pharma (India)
- Amneal Pharmaceuticals LLC. (U.S.)
Research Methodology: Global Vinflunine Market
Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.